JP2015512948A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512948A5
JP2015512948A5 JP2015505961A JP2015505961A JP2015512948A5 JP 2015512948 A5 JP2015512948 A5 JP 2015512948A5 JP 2015505961 A JP2015505961 A JP 2015505961A JP 2015505961 A JP2015505961 A JP 2015505961A JP 2015512948 A5 JP2015512948 A5 JP 2015512948A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
colchicine
composition according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015505961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512948A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/036474 external-priority patent/WO2013155478A1/en
Publication of JP2015512948A publication Critical patent/JP2015512948A/ja
Publication of JP2015512948A5 publication Critical patent/JP2015512948A5/ja
Pending legal-status Critical Current

Links

JP2015505961A 2012-04-13 2013-04-12 ハロフェナートまたはハロフェン酸および抗炎症剤を用いる痛風に罹っている患者の高尿酸血症の治療方法 Pending JP2015512948A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624186P 2012-04-13 2012-04-13
US61/624,186 2012-04-13
PCT/US2013/036474 WO2013155478A1 (en) 2012-04-13 2013-04-12 Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent

Publications (2)

Publication Number Publication Date
JP2015512948A JP2015512948A (ja) 2015-04-30
JP2015512948A5 true JP2015512948A5 (enExample) 2016-06-02

Family

ID=49325641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015505961A Pending JP2015512948A (ja) 2012-04-13 2013-04-12 ハロフェナートまたはハロフェン酸および抗炎症剤を用いる痛風に罹っている患者の高尿酸血症の治療方法

Country Status (15)

Country Link
US (1) US20130274331A1 (enExample)
EP (1) EP2836209A4 (enExample)
JP (1) JP2015512948A (enExample)
KR (1) KR20150002799A (enExample)
CN (1) CN104602686A (enExample)
AU (1) AU2013245675B2 (enExample)
CA (1) CA2870014A1 (enExample)
CL (1) CL2014002728A1 (enExample)
EA (1) EA028495B1 (enExample)
HK (1) HK1204913A1 (enExample)
IL (1) IL235154A0 (enExample)
MX (1) MX2014012376A (enExample)
PH (1) PH12014502282A1 (enExample)
SG (1) SG11201406495UA (enExample)
WO (1) WO2013155478A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894417C (en) 2012-11-02 2019-09-10 Murray & Poole Enterprises, Ltd. Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US20160081936A1 (en) 2013-04-16 2016-03-24 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
JP2023035118A (ja) * 2021-08-31 2023-03-13 国立大学法人広島大学 体液サンプリング容器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
BRPI0909299B1 (pt) * 2008-03-13 2021-11-23 Wellstat Therapeutics Corporation Compostos e métodos para redução de ácido úrico
US20090232745A1 (en) * 2008-03-14 2009-09-17 Intelliherb, Inc. Licorice lollipop that inhibits dental caries formation
US20100137235A1 (en) * 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
CN104066427A (zh) * 2011-11-04 2014-09-24 西玛贝医药公司 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法
WO2013066353A1 (en) * 2011-11-04 2013-05-10 Metabolex, Inc. Methods for treating gout flares
US9060987B2 (en) * 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
KR101848122B1 (ko) * 2011-11-04 2018-04-11 사이머베이 쎄라퓨틱스, 인코퍼레이티드 환자 부분모집단에서의 통풍 치료 방법

Similar Documents

Publication Publication Date Title
JP2012193216A5 (enExample)
JP2012255026A5 (enExample)
JP2013525444A5 (enExample)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2014507446A5 (enExample)
JP2016518337A5 (enExample)
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP2014526503A5 (enExample)
JP2013014622A5 (enExample)
PE20142353A1 (es) Ansolvatos de sal de noribogaina
JP2015155440A5 (enExample)
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
JP2013522326A5 (enExample)
JP2015533163A5 (enExample)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2013541583A5 (enExample)
JP2015512948A5 (enExample)
JP2015516419A5 (enExample)
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
RU2016112257A (ru) Композиция для лечения гипертензии и/или фиброза
JP2016515550A5 (enExample)
RU2013157398A (ru) Композиция
JP2014518280A5 (enExample)
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου